Lassus 1984.

Study characteristics
Methods	Trial design: randomised, double‐blind, parallel study Trial registration number: not reported Country: Finland Outpatient or hospital: Department of Dermatology, Helsinki University Central Hospital Date trial conducted: not reported Duration of trial participation: 2 weeks Inclusion criteria: · Disease present for at least 1 month and diagnosed as stable or worsening for more than 1 week · Each child manifested three disease signs of AD (erythema, induration, and pruritus) with a total severity score of 6 or more, when each sign was graded as follows: 0 = absent; 1 = mild; 2 = moderate; 3 = severe Exclusion criteria: not reported Additional design details: none
Participants	Total number randomised: 43 participants (22 to apply the intervention and 21 to apply the comparator) Age: 5 to 11 years Sex: female n = 27, male n = 16 Ethnicity: white Duration of eczema: present for at least 1 month Severity of eczema: 67% of the patients had up to 25% of the BSA involved with AD. Body site: lesions on the face, neck, trunk, and upper and lower extremities were included as study areas. Number of withdrawals: no withdrawals Notes: none
Interventions	Run‐in details: none Intervention: alclometasone dipropionate 0.05% cream used twice daily for 14 days · Concurrent treatment: not reported · Other key information: none Comparator: clobetasone butyrate 0.05% cream used twice daily for 14 days · Concurrent treatment: not reported · Other key information: none Concurrent treatments received alongside both intervention and comparator: not reported Notes: none
Outcomes	· Disease signs graded in preselected target areas using the scale: 0 = absent; 1 = mild; 2 = moderate; 3 = severe · The investigator globally evaluated improvement in the overall disease condition · AE
Notes	Funding source: not reported Declarations of interest: not declared Original language of publication: English Other: this study has previously been extracted by this group; some content is reproduced from Lax 2022.